Diagnostic biomarkers for Parkinson's disease: focus on a-synuclein in cerebrospinal fluid
Diagnostic biomarkers for Parkinson's disease: focus on a-synuclein in cerebrospinal fluid
复制标题
DOI：
10.1016/j.parkreldis.2018.11.016
复制
发表时间：
2019-02-01
影响因子：
4.1
通讯作者：
Kalia, Lorraine V.
中科院分区：
文献类型：
--
作者：
Kalia, Lorraine V.
诊断生物标记物是检测或确认疾病的存在或识别具有疾病亚型的个人的措施。对于帕金森病，与阿尔茨海默病和克雅氏病等其他神经退行性疾病不同，诊断生物标记物仍然难以捉摸，因为还没有可用的或批准用于临床的生物标记物。高准确度诊断早期或前驱帕金森氏病的生物标志物将显著提高临床实践以及推进临床治疗试验。许多证据支持α-突触核蛋白在帕金森氏病的病理生理学中的作用，因此，正在进行的识别帕金森病生物标志物的主要努力旨在测量外周组织和生物液中的α-突触核蛋白，包括脑脊液。这项工作仍处于生物标记物开发的早期阶段，并伴随着失败和胜利。本文综述了脑脊液中α-突触核蛋白作为帕金森病诊断标记物的研究进展，包括总α-突触核蛋白、寡聚体和磷酸化的α-突触核蛋白以及α-突触核蛋白的种子活性。
Diagnostic biomarkers are measures that detect or confirm the presence of a disease or identify individuals with a subtype of the disease. For Parkinson's disease, unlike other neurodegenerative diseases such as Alzheimer's disease and Creutzfeldt-Jakob disease, diagnostic biomarkers remain elusive as none are yet available or approved for clinical use. A biomarker to diagnose early or prodromal Parkinson's disease with high accuracy would significantly enhance clinical practice as well as advance clinical therapeutic trials. Multiple lines of evidence support a role of a-synuclein in the pathophysiology of Parkinson's disease and hence major ongoing efforts to identify biomarkers for Parkinson's disease are aimed at measuring alpha-synuclein in peripheral tissues and biofluids, including cerebrospinal fluid. This work is still in the early stages of biomarker development and has been accompanied by both losses and victories. Here, alpha-synuclein in cerebrospinal fluid as a diagnostic marker for Parkinson's disease is reviewed, including measures of total alpha-synuclein, oligomeric and phosphorylated alpha-synuclein, and seeding activity of alpha-synuclein.